Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients (2013)

  • Authors:
  • USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; SIMOES, BELINDA PINTO - FMRP
  • USP Schools: FCFRP; FMRP
  • DOI: 10.1007/s12032-013-0555-2
  • Subjects: IDOSOS; DOENÇAS HEMATOLÓGICAS; PROTEÍNAS QUINASES; PROGNÓSTICO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s12032-013-0555-2 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Medical Oncology

    ISSN: 1357-0560

    Citescore - 2017: 2.04

    SJR - 2017: 0.757

    SNIP - 2017: 0.591


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP2476177pcd 2476177 Estantes Deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SOUZA, M. C; RODRIGUES, C. A; SILVA, M. R. R; et al. Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients. Medical Oncology, Totowa, v. 30, n. 2, 2013. Disponível em: < http://dx.doi.org/10.1007/s12032-013-0555-2 > DOI: 10.1007/s12032-013-0555-2.
    • APA

      Souza, M. C., Rodrigues, C. A., Silva, M. R. R., Ribeiro, J., Tognon, R., Castro, F. A. de, et al. (2013). Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients. Medical Oncology, 30( 2). doi:10.1007/s12032-013-0555-2
    • NLM

      Souza MC, Rodrigues CA, Silva MRR, Ribeiro J, Tognon R, Castro FA de, Simoes BP, Souto EX, Chauffaille ML. Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients [Internet]. Medical Oncology. 2013 ; 30( 2):Available from: http://dx.doi.org/10.1007/s12032-013-0555-2
    • Vancouver

      Souza MC, Rodrigues CA, Silva MRR, Ribeiro J, Tognon R, Castro FA de, Simoes BP, Souto EX, Chauffaille ML. Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients [Internet]. Medical Oncology. 2013 ; 30( 2):Available from: http://dx.doi.org/10.1007/s12032-013-0555-2

    Referências citadas na obra
    Chauffaille ML. Alterações cromossômicas em síndrome mielodisplásica. Rev Bras Hematol Hemoter. 2006;28(3):182–7.
    Santos LC, Chauffaille ML, Ribeiro JC, Silva NP, Cerutti J, Silva MR. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Rev Bras Hematol Hemoter. 2011;33(6):417–24.
    Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.
    Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–65.
    Cervantes F, Pereira A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep. 2012;7(1):43–9.
    Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29(4):2379–84.
    Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D. European group for blood and marrow transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219–34.
    Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–8.
    Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684–90.
    Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083–8.
    Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857–8.
    Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.
    Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.
    Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: France, International Agency for Research on Cancer Press; 2001. p. 17–44.
    Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255–9.
    Shaffer LG, Slovak ML, Campbel LJ. ISCN 2009—An International System for Human Cytogenetic Nomeclature. Basel: S. Karger; 2009. 2009.
    Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–30.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4ª ed. Lyon: IARC; 2008.
    Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.
    Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine. 1976;24(4):272–80.
    Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol. 1978;40(2):205–17.
    Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 1983;54(1):79–89.
    Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine. 1983;62(6):353–71.
    Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70(4):397–401.
    Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol. 1988;40(4):355–61.
    Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75(1):4–9.
    Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia. 2012;26(6):1439–41.